Header Logo

Connection

Ajaypal Singh to Hematinics

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Hematinics.
Ajaypal Singh
Connection Strength
15.445
Hematinics
  1. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant. 2023 07 31; 38(8):1890-1897.
    View in: PubMed
    Score: 0.883
  2. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). Am J Nephrol. 2023; 54(1-2):1-13.
    View in: PubMed
    Score: 0.854
  3. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
    View in: PubMed
    Score: 0.836
  4. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
    View in: PubMed
    Score: 0.814
  5. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
    View in: PubMed
    Score: 0.809
  6. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
    View in: PubMed
    Score: 0.783
  7. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
    View in: PubMed
    Score: 0.783
  8. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. Semin Dial. 2013 Sep-Oct; 26(5):531-4.
    View in: PubMed
    Score: 0.437
  9. Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol. 2012 Nov; 8(11):616-8.
    View in: PubMed
    Score: 0.416
  10. Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61.
    View in: PubMed
    Score: 0.403
  11. Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int. 2011 Sep; 80(6):569-71.
    View in: PubMed
    Score: 0.387
  12. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):420-4.
    View in: PubMed
    Score: 0.361
  13. Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8.
    View in: PubMed
    Score: 0.359
  14. Diabetes, anemia and CKD: Why TREAT? Curr Diab Rep. 2010 Aug; 10(4):291-6.
    View in: PubMed
    Score: 0.359
  15. The etiology of anemia in heart failure. Preface. Heart Fail Clin. 2010 Jul; 6(3):xvii-xviii.
    View in: PubMed
    Score: 0.356
  16. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail Clin. 2010 Jul; 6(3):323-32.
    View in: PubMed
    Score: 0.356
  17. Anemia in chronic kidney disease: new advances. Heart Fail Clin. 2010 Jul; 6(3):347-57.
    View in: PubMed
    Score: 0.356
  18. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol. 2010; 31(6):552-6; discussion 563-4.
    View in: PubMed
    Score: 0.354
  19. ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol. 2010 Apr; 21(4):543-6.
    View in: PubMed
    Score: 0.350
  20. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
    View in: PubMed
    Score: 0.348
  21. Should we keep hemoglobin levels as a viable outcome measure? Nephrol News Issues. 2010 Mar; 24(3):15-6, 18.
    View in: PubMed
    Score: 0.348
  22. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010 Jan; 21(1):2-6.
    View in: PubMed
    Score: 0.344
  23. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Am J Kidney Dis. 2008 Dec; 52(6 Suppl):S5-13.
    View in: PubMed
    Score: 0.319
  24. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90.
    View in: PubMed
    Score: 0.309
  25. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim.
    View in: PubMed
    Score: 0.295
  26. The FDA black box for EPO: what should nephrologists do? Nephrol News Issues. 2007 May; 21(6):55-6, 58-9.
    View in: PubMed
    Score: 0.286
  27. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9.
    View in: PubMed
    Score: 0.286
  28. Anaemia of CKD--the CHOIR study revisited. Nephrol Dial Transplant. 2007 Jul; 22(7):1806-10.
    View in: PubMed
    Score: 0.285
  29. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98.
    View in: PubMed
    Score: 0.277
  30. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. Nephrol Nurs J. 2005 Mar-Apr; 32(2):199-206; quiz 207-8.
    View in: PubMed
    Score: 0.246
  31. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int. 2023 06; 103(6):1180-1192.
    View in: PubMed
    Score: 0.214
  32. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
    View in: PubMed
    Score: 0.206
  33. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.160
  34. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
    View in: PubMed
    Score: 0.148
  35. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2016 Dec; 68(6):873-881.
    View in: PubMed
    Score: 0.137
  36. Cause of Death in Patients With Diabetic CKD Enrolled in the?Trial to Reduce Cardiovascular Events With Aranesp Therapy?(TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
    View in: PubMed
    Score: 0.125
  37. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
    View in: PubMed
    Score: 0.109
  38. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
    View in: PubMed
    Score: 0.105
  39. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401.
    View in: PubMed
    Score: 0.101
  40. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
    View in: PubMed
    Score: 0.090
  41. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
    View in: PubMed
    Score: 0.085
  42. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
    View in: PubMed
    Score: 0.083
  43. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
    View in: PubMed
    Score: 0.079
  44. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9.
    View in: PubMed
    Score: 0.075
  45. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84.
    View in: PubMed
    Score: 0.070
  46. Ferric pyrophosphate citrate (Triferic?) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2019-26.
    View in: PubMed
    Score: 0.032
  47. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.